Development of patient derived organoids for cancer drug screening applications

Acta Histochem. 2022 May;124(4):151895. doi: 10.1016/j.acthis.2022.151895. Epub 2022 Apr 26.

Abstract

Cancer is a disease characterised by abnormal cell growth that can invade or spread to other regions of the body. Organoids are three-dimensional ex vivo tissue cultures made from embryonic stem cells, induced pluripotent stem cells, progenitor cells or tissue that serve as a physiological model for cancer research. These are designed to recapitulate the in vivo properties of tumours. Importantly, effective recapitulation of the structure of tissues and function is believed to predict patient response, allowing for the creation of personalised therapy in a timely manner that may be used in the clinic. This Review discusses the pre-clinical model and different types of human organoids as models for the development of high throughput drug screening and also aims to highlight how organoids are shaping the future of cancer research.

Keywords: Cancer; Organoid; Pre-clinical model; Progenitor cells; Stem cell; Tissue.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Drug Evaluation, Preclinical
  • Early Detection of Cancer
  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism
  • Organoids / metabolism

Substances

  • Antineoplastic Agents